PROs from DeLLphi-304 evaluating tarlatamab vs chemotherapy in SCLC
Автор: VJOncology
Загружено: 2025-11-18
Просмотров: 103
Описание:
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, discusses patient-reported outcomes from Phase III DeLLphi-304 (NCT05740566) of tarlatamab versus chemotherapy in previously treated small cell lung cancer (SCLC). Improvements in symptoms such as dyspnea, cough, and chest pain were reported in the tarlatamab arm, along with better physical functioning, global health status, and reduced treatment burden. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
